← Back to Patent Explorer
US4460591A Expired / Lapsed US ⏱️ 0.0 years remaining

8,10-Dideazaminopterins

Assignee: SRI International Inc
•
Filing: 1982-08-26
•
Granted: 1984-07-17
•
Expires: 2002-08-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract 8,10-Dideazaminopterins of the formula <IMAGE> where R is hydrogen or alkyl of 1 to about 8 carbon atoms and their carboxylate and acid addition salts are described. These compounds exhibit antineoplastic activity that is similar to but more effective than methotrexate.

Inventors

  • 👤 Joseph I. DeGraw
  • 👤 Lawrence F. Kelly
  • 👤 Francis M. Sirotnak

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 15:23
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 25 words
A compound of the formula ##STR6## where R is a hydrogen or alkyl of 1 to about 8 carbon atoms, and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim 25 words
A compound of the formula ##STR6## where R is a hydrogen or alkyl of 1 to about 8 carbon atoms, and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim 13 words
The compound of claim 1 wherein R is hydrogen, methyl, propyl, or amyl.
Claim 4
Dependent Claim 13 words
The compound of claim 1 wherein said pharmaceutically acceptable salts are sodium salts.
Claim 5
Dependent Claim 1 words
8,10-dideazaminopterin.
Claim 6
Dependent Claim 1 words
8,10-dideazaminopterin.
Claim 7
Dependent Claim 1 words
10-Methyl-8,10-dideazaminopterin.
Claim 8
Dependent Claim 1 words
10-Methyl-8,10-dideazaminopterin.
Claim 9
Dependent Claim 1 words
10-Propyl-8,10-dideazaminopterin.
Claim 10
Dependent Claim 1 words
10-Propyl-8,10-dideazaminopterin.
Claim 11
Dependent Claim 1 words
10-Amyl-8,10-dideazaminopterin.
Claim 12
Dependent Claim 1 words
10-Amyl-8,10-dideazaminopterin.
Claim 13
Dependent Claim 27 words
An antineoplastic composition comprising a therapeutically effective amount of the compound of claim 1, 2, 3, 4, 5, 6, or 7 combined with a pharmaceutically acceptable carrier.
Claim 14
Dependent Claim 34 words
An antineoplastic composition for parenteral administration comprising a therapeutically effective amount of a sodium salt of the compound of claim 1, 2, 4, 5, 6, or 7 dissolved in a pharmaceutically acceptable aqueous solvent.
Claim 15
Dependent Claim 32 words
A method of inhibiting neoplastic growth in a living animal comprising administering a therapeutically effective amount of the compound of claim 1, 2, 3, 4, 5, 6, or 7 to the animal.
Claim 16
Dependent Claim 42 words
A method of inhibiting neoplastic growth in a living animal comprising administering a therapeutically effective amount of an aqueous solution of a sodium salt of the compound of claim 1, 2, 4, 5, 6, or 7 to the animal intravenously or subcutaneously.

References Cited (Backward Citations)

GB1534238A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-07-17 1988-01-16 1988-07-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-07-17 1992-01-16 1992-07-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-07-17 1996-01-16 1996-07-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag